The role of afatinib in patients with EGFR NSCLC

Accelerated tumour growth due to immunotherapy: Fact or fiction?

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer

Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma

KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases